TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33348088

Group type: EXPERIMENTAL
Intervention: Cognitive functioning questionnaire from the Medical Outcome Study (MOS)
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: QLQ-C30 cognitive functioning (CF) subscale
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: NCF test scores
Number of subjects: 546
Study: 35229694

Group type: EXPERIMENTAL
Intervention: Active Sentry handpiece + Intrepid Hybrid tip (Group 1)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Centurion Ozil handpiece + Intrepid Balanced tip (Group 2)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 168
Study: 32100261

Group type: EXPERIMENTAL
Intervention: PegIFNα-2a or PegIFNα-2b (48-week treatment)
Number of subjects: 727
Study: 34412009

Group type: EXPERIMENTAL
Intervention: Novel quantitative digital image analysis methodology (DYNAMIKA®)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Images with good quality scores
Number of subjects: 0

Group type: COMPARATOR
Intervention: RA Magnetic Resonance Imaging Score (RAMRIS)
Number of subjects: 0
Study: 32406725

Group type: EXPERIMENTAL
Intervention: Fitbit (n=101)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Control (n=161)
Number of subjects: 262
Study: 35833083

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided brachial plexus block anesthesia
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional anatomic localization brachial plexus block anesthesia
Number of subjects: 82
Study: 35816301

Group type: EXPERIMENTAL
Intervention: Deep learning-based prediction method
Number of subjects: 557

Group type: COMPARATOR
Intervention: General Movement Assessment (GMA) tool
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Deep learning method
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Deep learning prediction model
Number of subjects: 557
Study: 34047235

Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA for 20 minutes) + Aerobic Exercise (30 minutes cycling at moderate intensity)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham tDCS (10 s) + Aerobic Exercise (30 minutes cycling at moderate intensity)
Number of subjects: 20
Study: 35236650

Group type: EXPERIMENTAL
Intervention: Levothyroxine combined with methimazole
Number of subjects: 102

Group type: COMPARATOR
Intervention: Methimazole treatment alone
Number of subjects: 102
Study: 32479160

Group type: EXPERIMENTAL
Intervention: Suicide prevention PSAs (three different PSAs)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Control PSA
Number of subjects: 349
Study: 32795310

Group type: EXPERIMENTAL
Intervention: Canola oil (CO) 25 mL/day for 6 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Olive oil (OO) 25 mL/day for 6 weeks
Number of subjects: 48
Study: 35526010

Group type: EXPERIMENTAL
Intervention: Continuous and progressive rehabilitation and care across sectors including 12 weeks of progressive resistance exercises initiated 1–2 days after discharge, outreach nurse assessment, and a hotline for medical advice
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual rehabilitation and care
Number of subjects: 50
Study: 34322782

Group type: EXPERIMENTAL
Intervention: Internal attentional focus
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: External attentional focus
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study: 35180696

Group type: EXPERIMENTAL
Intervention: T-VIM (tractography-based targeting of the ventral intermediate nucleus)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: T-VIM
Number of subjects: 0
Study: 33438825

Group type: EXPERIMENTAL
Intervention: Educational-counseling program based on precede-proceed model during pregnancy
Number of subjects: 130

Group type: COMPARATOR
Intervention: Routine pregnancy care (Control)
Number of subjects: 130
Study: 32111244

Group type: EXPERIMENTAL
Intervention: Decolonisation for Methicillin Sensitive Staphylococcus aureus (MSSA) to reduce post‐operative infection (QIST: Infection)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Anaemia optimisation programme to reduce peri‐operative blood transfusions (QIST: Anaemia)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual practice (control group for QIST: Infection)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual practice (control group for QIST: Anaemia)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Patient-level secondary outcomes
Number of subjects: 40
Study: 33506521

Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy (ACT) orientated anger management training
Number of subjects: 0
Study: 33686040

Group type: EXPERIMENTAL
Intervention: Scalpel
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Electrosurgery
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Laser (Biolase)
Number of subjects: 30
Study: 35158207

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 162
Study: 34261408

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Suicidal ideation
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Positive symptom scores
Number of subjects: 298

Group type: COMPARATOR
Intervention: Negative symptoms
Number of subjects: 298

Group type: COMPARATOR
Intervention: Social functioning
Number of subjects: 298
Study: 34371884

Group type: EXPERIMENTAL
Intervention: tRES-HESP treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35044692

Group type: EXPERIMENTAL
Intervention: Ridge preservation performed after tooth extraction
Number of subjects: 57
Study: 34167959

Group type: EXPERIMENTAL
Intervention: Nerinetide
Number of subjects: 1099
Study: 32561125

Group type: COMPARATOR
Intervention: Symptoms listed in the NICE guidelines
Number of subjects: 574

Group type: COMPARATOR
Intervention: Modified Goff Index symptoms
Number of subjects: 574

Group type: COMPARATOR
Intervention: Each additional presenting symptom
Number of subjects: 574

Group type: COMPARATOR
Intervention: Abdominal pain and loss of appetite/feeling full
Number of subjects: 574
Study: 36006634

Group type: EXPERIMENTAL
Intervention: Anti-vascular endothelial growth factor therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference category
Number of subjects: 0
Study: 33641601

Group type: EXPERIMENTAL
Intervention: Calciphylaxis patients (20 patients)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-calciphylaxis patients (40 patients)
Number of subjects: 60
Study: 32248190

Group type: EXPERIMENTAL
Intervention: Inhaled tiotropium (5 μg, two inhalations of 2.5 μg) for at least 2 weeks before esophagectomy and continued until postoperative evaluation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 32
Study: 36294026

Group type: EXPERIMENTAL
Intervention: Comorbidity burden (measured by SPI-II)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: SPI-II risk groups (low, medium, high)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Individual comorbid conditions
Number of subjects: 97
Study: 34919613

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 43

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both
Number of subjects: 43
Study: 34184315

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 96

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 96
Study: 32067040

Group type: EXPERIMENTAL
Intervention: EBV infection in infants at week 50
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: EBV DNA testing in infants
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Shedding of EBV in breast milk
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: EBV infant infection at week 50
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Clinical SAEs in infants
Number of subjects: 201
Study: 33528457

Group type: EXPERIMENTAL
Intervention: ionic‐sonic electric toothbrush
Number of subjects: 78

Group type: COMPARATOR
Intervention: manual toothbrush
Number of subjects: 78
Study: 32358544

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor (empagliflozin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulfonylurea
Number of subjects: 0
Study: 35659328

Group type: EXPERIMENTAL
Intervention: Focal ARDS
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Non-focal ARDS
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: McCabe score
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Comorbidities
Number of subjects: 360
Study: 34597366

Group type: EXPERIMENTAL
Intervention: Quizartinib + low-dose ara-C (LDAC)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Low-dose ara-C (LDAC) alone
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Quizartinib + LDAC
Number of subjects: 202
Study: 32389019

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 55

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 55
Study: 35297467

Group type: EXPERIMENTAL
Intervention: 5g PHGG mixed with 200ml water per day for 4 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: 200ml water for 4 weeks (Control)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 52
Study: 32630786

Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum subsp. longum OLP-01 (1.5 × 10^10 CFU/day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 36180953

Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Standard Moist Wound Care (SMWC)
Number of subjects: 368
Study: 34175999

Group type: EXPERIMENTAL
Intervention: EUCAST guidelines
Number of subjects: 237

Group type: COMPARATOR
Intervention: CLSI guidelines
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Disk diffusion according to EUCAST guidelines
Number of subjects: 237
Study: 32160891

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI)
Number of subjects: 612

Group type: COMPARATOR
Intervention: Relaxation training (RT)
Number of subjects: 612
Study: 33526448

Group type: EXPERIMENTAL
Intervention: Journals with strict CONSORT endorsement (BMJ and JAMA)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Journals with less strict CONSORT endorsement (NEJM and Ann Intern Med)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: The Lancet
Number of subjects: 258

Group type: COMPARATOR
Intervention: Journals that recommend adherence to CONSORT
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Journals that require a completed checklist for CONSORT adherence
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Overall RCTs
Number of subjects: 258
Study: 33371851

Group type: EXPERIMENTAL
Intervention: Stress management training program (8 sessions over one month)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 92
Study: 33902162

Group type: EXPERIMENTAL
Intervention: Altitude of 2,590 m
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: COPDDesat (SpO2 <90% for >30% of night‐time)
Number of subjects: 35
Study: 32595159

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG plus usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care without probiotics
Number of subjects: 0
Study: 34142915

Group type: EXPERIMENTAL
Intervention: Life skills training intervention (9 sessions)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 80
Study: 34235908

Group type: EXPERIMENTAL
Intervention: Buccal midazolam
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam
Number of subjects: 36
Study: 32224420

Group type: EXPERIMENTAL
Intervention: 7-day self-reported nicotine patch use
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: 3-week self-reported nicotine patch use
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: 11-week self-reported nicotine patch use
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: 3-day self-reported nicotine patch use
Number of subjects: 198
Study: 33655432

Group type: EXPERIMENTAL
Intervention: Zinc sulfate supplementation (220 mg/day, containing 50 mg Zn) for 8 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (220 mg corn starch) for 8 weeks
Number of subjects: 46
Study: 34048947

Group type: EXPERIMENTAL
Intervention: Sintilimab plus GP
Number of subjects: 357

Group type: COMPARATOR
Intervention: Placebo plus GP
Number of subjects: 357
Study: 32485095

Group type: COMPARATOR
Intervention: Testosterone enanthate (TE) 50, 125, 300, or 600 mg/week plus placebo for 20 weeks in 5aR trial
Number of subjects: 180

Group type: COMPARATOR
Intervention: Testosterone enanthate (TE) 100 mg/week plus placebo for 6 months in OPTIMEN trial
Number of subjects: 180
Study: 35078438

Group type: EXPERIMENTAL
Intervention: Patient Navigator (usual care + Patient Navigator)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control condition (usual care)
Number of subjects: 45
Study: 33183908

Group type: EXPERIMENTAL
Intervention: Cannabis use during treatment
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Latency to cannabis dependence
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Age of cannabis use onset
Number of subjects: 302
Study: 35753816

Group type: EXPERIMENTAL
Intervention: Vascularized corticoperiosteal bone flap with only arterial anastomosis (Group B)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Vascularized corticoperiosteal bone flap with both arterial and venous anastomosis (Group A)
Number of subjects: 49
Study: 32917948

Group type: EXPERIMENTAL
Intervention: Community-based intervention involving 36 phone calls and three home visits over 2 years
Number of subjects: 410

Group type: COMPARATOR
Intervention: Usual post-discharge care (Control)
Number of subjects: 410
Study: 32465052

Group type: EXPERIMENTAL
Intervention: CD4+ CD57+ PD1+ T cells frequency above 7.8% in BAL
Number of subjects: 50

Group type: COMPARATOR
Intervention: CD4+ CD57+ PD1+ T cells frequency
Number of subjects: 50
Study: 35457474

Group type: EXPERIMENTAL
Intervention: Parenting Inside Out (PIO) intervention
Number of subjects: 359

Group type: COMPARATOR
Intervention: services-as-usual (control)
Number of subjects: 359
Study: 33985364

Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg plus hydrochlorothiazide 12.5 mg daily (active treatment)
Number of subjects: 12705

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg daily (active treatment)
Number of subjects: 12705

Group type: EXPERIMENTAL
Intervention: Combination of candesartan plus hydrochlorothiazide and rosuvastatin (active treatment)
Number of subjects: 12705

Group type: COMPARATOR
Intervention: Double placebo (control)
Number of subjects: 12705
Study: 32791295

Group type: EXPERIMENTAL
Intervention: a-PDT with toluidine blue (TB)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Irrigation with normal saline
Number of subjects: 21
Study: 35658056

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD) for 3 weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: High-carbohydrate low-fat diet (HCLF) for 3 weeks
Number of subjects: 11
Study: 33381989

Group type: EXPERIMENTAL
Intervention: Core strength training for 10 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 48
Study: 35950355

Group type: EXPERIMENTAL
Intervention: Vitamin E (group A, n=30)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Supragingival scaling with vitamin C (group C, n=29)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Vitamin C (group B, n=30)
Number of subjects: 89
Study: 33201520

Group type: COMPARATOR
Intervention: Org 48,775-0 (30 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Org 48,775-0 (70 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Org 48,775-0 (150 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Org 48,775-0 (≥30 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33327312

Group type: EXPERIMENTAL
Intervention: ω‐3 PUFAs, 640 mg t.i.d during chemotherapy and 1 month after treatment
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study: 35570329

Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone (8 mg)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (8 mg)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Dexamethasone (both routes)
Number of subjects: 95
Study: 32599655

Group type: EXPERIMENTAL
Intervention: idelalisib + anti-CD20 (rituximab or ofatumumab)
Number of subjects: 481

Group type: COMPARATOR
Intervention: anti-CD20 alone
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: idelalisib + anti-CD20
Number of subjects: 481
Study: 35287430

Group type: EXPERIMENTAL
Intervention: Low-dose COH04S1 (1·0×10^7 PFU)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Medium-dose COH04S1 (1·0×10^8 PFU)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: High-dose COH04S1 (2·5×10^8 PFU)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Low-dose COH04S1 followed by placebo
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Combined dose levels of COH04S1
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: COH04S1 (any dose)
Number of subjects: 56
Study: 33239044

Group type: EXPERIMENTAL
Intervention: Eculizumab (1200 mg) administered intravenously < 12 h, on day 3 and on day 7 after ictus, with prophylactic antibiotics for 4 weeks.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Not applicable (control group).
Number of subjects: 40
Study: 36216769

Group type: EXPERIMENTAL
Intervention: Implementation of the APDS-Diversity and Inclusion Committee (APDS-DIC) in 2017
Number of subjects: 864

Group type: COMPARATOR
Intervention: Before APDS-DIC inception (2008-2016)
Number of subjects: 864
Study: 32829739

Group type: EXPERIMENTAL
Intervention: Standardised enteral feeding protocol with cerebro-somatic near-infrared spectroscopy
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Standardised enteral feeding protocol without cerebro-somatic near-infrared spectroscopy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control cohort (historical comparison)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Feeding cohort
Number of subjects: 33
Study: 36411708

Group type: EXPERIMENTAL
Intervention: Otago exercise programme (OEP)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Routine rehabilitation training (Control)
Number of subjects: 77
Study: 33745119

Group type: EXPERIMENTAL
Intervention: Apple juice/preferred fluids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electrolyte maintenance solution
Number of subjects: 0
Study: 35545122

Group type: EXPERIMENTAL
Intervention: CADe-assisted colonoscopy
Number of subjects: 800

Group type: COMPARATOR
Intervention: HDWL colonoscopy
Number of subjects: 800
Study: 33019798

Group type: EXPERIMENTAL
Intervention: Gastrodia-uncaria granules (5 to 10 g twice daily for 4 weeks)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo (5 to 10 g twice daily for 4 weeks)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Gastrodia-uncaria granules
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 33436683

Group type: EXPERIMENTAL
Intervention: Ranibizumab monotherapy
Number of subjects: 59

Group type: COMPARATOR
Intervention: Combination therapy (ranibizumab + focal/grid short-pulse laser)
Number of subjects: 59
Study: 32219478

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus acidophilus, Lactobacillus bulgaricus, Streptococcus thermophilus, Bifidobacterium bifidum) administered twice a day for 5 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo capsules administered twice a day for 5 weeks
Number of subjects: 32
Study: 33309213

Group type: EXPERIMENTAL
Intervention: Screw access channel group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional crown group
Number of subjects: 40
Study: 34825538

Group type: EXPERIMENTAL
Intervention: Yoga nidra
Number of subjects: 41

Group type: COMPARATOR
Intervention: Cognitive behavioural therapy for insomnia
Number of subjects: 41
Study: 32894702

Group type: EXPERIMENTAL
Intervention: Clinical score tool based on preoperative predictors of tympanosclerosis identified through multivariate logistic regression analysis.
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Clinical score tool including independent factors such as female sex, frequency-specific air-bone gap at 250 Hz ≥ 45 dB HL, aditus ad antrum blockage, type I and II eardrum calcification, and history of otitis media ≥ 10 years.
Number of subjects: 404
Study: 33989025

Group type: EXPERIMENTAL
Intervention: Gemcitabine and Cisplatin with Bevacizumab (GCB)
Number of subjects: 506

Group type: COMPARATOR
Intervention: Gemcitabine and Cisplatin with Placebo (GCP)
Number of subjects: 506
Study: 32804188

Group type: EXPERIMENTAL
Intervention: 10 mg of regular, oral sustained-release morphine twice daily for 4 weeks (with possibility to increase to 3 times daily after 1 or 2 weeks)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 10 mg of regular, oral sustained-release morphine
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 34648082

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) with dose-dense paclitaxel (80 mg/m2 on days 1, 8, and 15), carboplatin (AUC 6.0 mg/mL × min. on day 1), and bevacizumab (15 mg/kg on day 1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) with dose-dense TC-bevacizumab therapy
Number of subjects: 24
Study: 33975734

Group type: EXPERIMENTAL
Intervention: Intermittent caloric restriction
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Continuous caloric restriction
Number of subjects: 112
Study: 33379931

Group type: EXPERIMENTAL
Intervention: Machine learning model predicting perceived differences based on individual AFs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonindividual HRTFs
Number of subjects: 0
Study: 33402230

Group type: COMPARATOR
Intervention: Intramuscular haloperidol 5 mg plus promethazine 25 mg (HP)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intramuscular chlorpromazine 100 mg plus haloperidol 5 mg plus promethazine 25 mg (HPC)
Number of subjects: 100
Study: 32449896

Group type: EXPERIMENTAL
Intervention: Peritoneal flap
Number of subjects: 232

Group type: COMPARATOR
Intervention: Control (no peritoneal flap)
Number of subjects: 232
Study: 32863100

Group type: EXPERIMENTAL
Intervention: TENS associated with vocal therapy
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo group (electrodes placed, equipment off)
Number of subjects: 17
Study: 34028504

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0